Condition: Adrenoleukodystrophy · Adrenomyeloneuropathy · Metachromatic Leukodystrophy · Sponsor: Assistance Publique - Hôpitaux de Paris
This study is a national, non-randomized, open-label, multi-site with minimal risk study in adult with adrenomyeloneuropathy (AMN), childhood and adult subjects with cerebral ALD (cALD), juvenile/adult metachromatic leukodystrophy (MLD) and adults with leukoencephalopathy and axonal spheroids and pigmented glia (ALSP). 49 subjects will be enrolled with one blood sample collection during one of their medical follow-up visit. This trial will evaluate the role of innate immunity to influence disease progression in X-ALD, MLD and ALSP, and if the mutations related to these leukodystrophies result in a specific immune response leading to the pathogenesis.
This description comes directly from the study's public registry record.
Fanny MOCHEL · 01 57 27 44 82 · fanny.mochel@icm-institut.org
Christelle AUGER · christelle.auger@aphp.fr
Always discuss trial participation with your own doctor first.
| AP-HP Hôpital Bicêtre | Le Kremlin-Bicêtre, France | Recruiting |
| AP-HP Hôpital La Pitié Salpêtrière | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04925349